Octopamine
•Last Updated: September 28 2022
A metabolite of synephrine, Octopamine is a stimulant compound that is also thought to have minor fat burning effects. Banned by WADA due to its stimulatory properties, the direct fat burning claims may not be relevant and are effectively untested in humans.
Octopamine is most often used for
Last Updated: September 28 2022
Note that Octopamine is also known as:
- Norsynephrine
- p-hydroxyphenylethanolamine
- β-hydroxytyramine
- Norphen
- Norsympatol
- norfenefrine
What works and what doesn't?
Unlock the full potential of Examine
1.^Li B1, Tsing S, Kosaka AH, Nguyen B, Osen EG, Bach C, Chan H, Barnett JExpression of human dopamine beta-hydroxylase in Drosophila Schneider 2 cellsBiochem J.(1996 Jan 1)
2.^D'Andrea G1, Terrazzino S, Fortin D, Farruggio A, Rinaldi L, Leon AHPLC electrochemical detection of trace amines in human plasma and platelets and expression of mRNA transcripts of trace amine receptors in circulating leukocytesNeurosci Lett.(2003 Jul 31)
4.^Evans PD1, Maqueira BInsect octopamine receptors: a new classification scheme based on studies of cloned Drosophila G-protein coupled receptorsInvert Neurosci.(2005 Nov)
7.^Thevis M1, Koch A, Sigmund G, Thomas A, Schänzer WAnalysis of octopamine in human doping control samplesBiomed Chromatogr.(2012 May)
8.^Putzbach K1, Rimmer CA, Sharpless KE, Wise SA, Sander LCDetermination of bitter orange alkaloids in dietary supplement Standard Reference Materials by liquid chromatography with atmospheric-pressure ionization mass spectrometryAnal Bioanal Chem.(2007 Sep)
9.^Determination of para-synephrine and meta-synephrine positional isomers in bitter orange-containing dietary supplements by LC/UV and LC/MS/MS.()
10.^Ichikawa M1, Ryu K, Yoshida J, Ide N, Kodera Y, Sasaoka T, Rosen RTIdentification of six phenylpropanoids from garlic skin as major antioxidantsJ Agric Food Chem.(2003 Dec 3)
11.^Wu Z1, Zheng L, Li Y, Su F, Yue X, Tang W, Ma X, Nie J, Li HSynthesis and structure-activity relationships and effects of phenylpropanoid amides of octopamine and dopamine on tyrosinase inhibition and antioxidationFood Chem.(2012 Sep 15)
13.^Stohs SJPhysiological functions and pharmacological and toxicological effects of p-octopamineDrug Chem Toxicol.(2014 Mar 24)
14.^Brown CM1, McGrath JC, Midgley JM, Muir AG, O'Brien JW, Thonoor CM, Williams CM, Wilson VGActivities of octopamine and synephrine stereoisomers on alpha-adrenoceptorsBr J Pharmacol.(1988 Feb)
15.^Ibrahim KE, Couch MW, Williams CM, Fregly MJ, Midgley JMm-Octopamine: normal occurrence with p-octopamine in mammalian sympathetic nervesJ Neurochem.(1985 Jun)
16.^Pellati F1, Benvenuti SChromatographic and electrophoretic methods for the analysis of phenethylamine {corrected} alkaloids in Citrus aurantiumJ Chromatogr A.(2007 Aug 17)
17.^Premont RT1, Gainetdinov RR, Caron MGFollowing the trace of elusive aminesProc Natl Acad Sci U S A.(2001 Aug 14)
18.^Bunzow JR1, Sonders MS, Arttamangkul S, Harrison LM, Zhang G, Quigley DI, Darland T, Suchland KL, Pasumamula S, Kennedy JL, Olson SB, Magenis RE, Amara SG, Grandy DKAmphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptorMol Pharmacol.(2001 Dec)
19.^Xie Z1, Vallender EJ, Yu N, Kirstein SL, Yang H, Bahn ME, Westmoreland SV, Miller GMCloning, expression, and functional analysis of rhesus monkey trace amine-associated receptor 6: evidence for lack of monoaminergic associationJ Neurosci Res.(2008 Nov 15)
20.^Hengstmann JH, Konen W, Konen C, Eichelbaum M, Dengler HJBioavailability of m-octopamine in man related to its metabolismEur J Clin Pharmacol.(1975)
21.^Hengstmann JH, Konen W, Konen C, Eichelbaum M, Dengler HJThe physiological disposition of p-octopamine in manNaunyn Schmiedebergs Arch Pharmacol.(1974)
22.^D'Andrea G1, Nordera G, Pizzolato G, Bolner A, Colavito D, Flaibani R, Leon ATrace amine metabolism in Parkinson's disease: low circulating levels of octopamine in early disease stagesNeurosci Lett.(2010 Jan 29)
23.^Andrew R1, Best SA, Watson DG, Midgley JM, Reid JL, Squire IBAnalysis of biogenic amines in plasma of hypertensive patients and a control groupNeurochem Res.(1993 Nov)
24.^Suzuki O, Katsumata Y, Oya M, Matsumoto TOxidation of phenylethanolamine and octopamine by type A and type B monoamine oxidase. Effect of substrate concentrationBiochem Pharmacol.(1979 Aug 1)
25.^Youdim MB1, Finberg JPNew directions in monoamine oxidase A and B selective inhibitors and substratesBiochem Pharmacol.(1991 Jan 15)
26.^Castillo V1, Lizcano JM, Visa J, Unzeta MSemicarbazide-sensitive amine oxidase (SSAO) from human and bovine cerebrovascular tissues: biochemical and immunohistological characterizationNeurochem Int.(1998 Nov)
27.^James MI, Midgley JM, Williams CMThe metabolism and biosynthesis of (+/-)-o-octopamine and (+/-)-o-synephrine in the ratJ Pharm Pharmacol.(1983 Sep)
28.^Medana C1, Calza P, Giancotti V, Dal Bello F, Aragno M, Baiocchi CStudy of the photocatalytic transformation of synephrine: a biogenic amine relevant in anti-doping analysisAnal Bioanal Chem.(2013 Jan)
30.^Ibrahim KE, Midgley JM, Crowley JR, Williams CMThe mammalian metabolism of R-(-)-m-synephrineJ Pharm Pharmacol.(1983 Mar)
31.^Kleinau G1, Pratzka J, Nürnberg D, Grüters A, Führer-Sakel D, Krude H, Köhrle J, Schöneberg T, Biebermann HDifferential modulation of Beta-adrenergic receptor signaling by trace amine-associated receptor 1 agonistsPLoS One.(2011)
32.^Carpéné C1, Galitzky J, Fontana E, Atgié C, Lafontan M, Berlan MSelective activation of beta3-adrenoceptors by octopamine: comparative studies in mammalian fat cellsNaunyn Schmiedebergs Arch Pharmacol.(1999 Apr)
33.^Fregly MJ, Kelleher DL, Williams CMAdrenergic activity of ortho-, meta-, and para-octopaminePharmacology.(1979)
34.^Airriess CN1, Rudling JE, Midgley JM, Evans PDSelective inhibition of adenylyl cyclase by octopamine via a human cloned alpha 2A-adrenoceptorBr J Pharmacol.(1997 Sep)
35.^Cheng JT1, Shen CL, Jou TCInhibitory effect of octopamine on dopamine D-1 receptor in striatal homogenates of the ratNeurosci Res.(1990 Dec)
36.^Cheng JT1, Tsai JTOctopamine: an endogenous blocker of dopamine D-1 receptorsAdv Exp Med Biol.(1991)
37.^Tsai LH1, Cheng JTStimulatory effect of dopamine on acid secretion from the isolated rat stomachNeurosci Res.(1995 Jan)
38.^Cheng JT1, Hsieh-Chen SCOctopamine relaxes rabbit jejunal smooth muscle by selective activation of dopamine D1 receptorsNaunyn Schmiedebergs Arch Pharmacol.(1988 Oct)
39.^Li LB1, Reith MEInteraction of Na+, K+, and Cl- with the binding of amphetamine, octopamine, and tyramine to the human dopamine transporterJ Neurochem.(2000 Apr)
40.^Amejdki-Chab N1, Benmansour S, Costentin J, Bonnet JJEffects of several cations on the neuronal uptake of dopamine and the specific binding of {3H}GBR 12783: attempts to characterize the Na+ dependence of the neuronal transport of dopamineJ Neurochem.(1992 Nov)
41.^Li LB1, Cui XN, Reith MAIs Na(+) required for the binding of dopamine, amphetamine, tyramine, and octopamine to the human dopamine transporterNaunyn Schmiedebergs Arch Pharmacol.(2002 Apr)
42.^D'Andrea G1, D'Arrigo A, Dalle Carbonare M, Leon APathogenesis of migraine: role of neuromodulatorsHeadache.(2012 Jul-Aug)
43.^D'Andrea G1, Granella F, Leone M, Perini F, Farruggio A, Bussone GAbnormal platelet trace amine profiles in migraine with and without auraCephalalgia.(2006 Aug)
44.^D'Andrea G1, Terrazzino S, Leon A, Fortin D, Perini F, Granella F, Bussone GElevated levels of circulating trace amines in primary headachesNeurology.(2004 May 25)
45.^D'Andrea G1, D'Amico D, Bussone G, Bolner A, Aguggia M, Saracco MG, Galloni E, De Riva V, Colavito D, Leon A, Rosteghin V, Perini FThe role of tyrosine metabolism in the pathogenesis of chronic migraineCephalalgia.(2013 Aug)
46.^D'Andrea G1, Ostuzzi R, Francesconi F, Musco F, Bolner A, d'Onofrio F, Colavito DMigraine prevalence in eating disorders and pathophysiological correlationsNeurol Sci.(2009 May)
47.^D'Andrea G1, Ostuzzi R, Bolner A, Francesconi F, Musco F, d'Onofrio F, Colavito DStudy of tyrosine metabolism in eating disorders. Possible correlation with migraineNeurol Sci.(2008 May)
48.^Headache Classification Subcommittee of the International Headache SocietyThe International Classification of Headache Disorders: 2nd editionCephalalgia.(2004)
49.^Visentin V1, Morin N, Fontana E, Prévot D, Boucher J, Castan I, Valet P, Grujic D, Carpéné CDual action of octopamine on glucose transport into adipocytes: inhibition via beta3-adrenoceptor activation and stimulation via oxidation by amine oxidasesJ Pharmacol Exp Ther.(2001 Oct)
50.^Pizzinat N1, Marti L, Remaury A, Leger F, Langin D, Lafontan M, Carpéné C, Parini AHigh expression of monoamine oxidases in human white adipose tissue: evidence for their involvement in noradrenaline clearanceBiochem Pharmacol.(1999 Dec 1)
51.^Morin N1, Lizcano JM, Fontana E, Marti L, Smih F, Rouet P, Prévot D, Zorzano A, Unzeta M, Carpéné CSemicarbazide-sensitive amine oxidase substrates stimulate glucose transport and inhibit lipolysis in human adipocytesJ Pharmacol Exp Ther.(2001 May)
52.^Piwkowska A1, Rogacka D, Angielski S, Jankowski MHydrogen peroxide induces activation of insulin signaling pathway via AMP-dependent kinase in podocytesBiochem Biophys Res Commun.(2012 Nov 9)
53.^Marti L1, Morin N, Enrique-Tarancon G, Prevot D, Lafontan M, Testar X, Zorzano A, Carpéné CTyramine and vanadate synergistically stimulate glucose transport in rat adipocytes by amine oxidase-dependent generation of hydrogen peroxideJ Pharmacol Exp Ther.(1998 Apr)
54.^Flechtner-Mors M1, Jenkinson CP, Alt A, Adler G, Ditschuneit HHIn vivo alpha(1)-adrenergic lipolytic activity in subcutaneous adipose tissue of obese subjectsJ Pharmacol Exp Ther.(2002 Apr)
55.^Lafontan M1, Barbe P, Galitzky J, Tavernier G, Langin D, Carpéné C, Bousquet-Melou A, Berlan MAdrenergic regulation of adipocyte metabolismHum Reprod.(1997 Oct)
56.^Lawrence JC Jr, Larner JEvidence for alpha adrenergic activation of phosphorylase and inactivation of glycogen synthase in rat adipocytes. Effects of alpha and beta adrenergic agonists and antagonists on glycogen synthase and phosphorylaseMol Pharmacol.(1977 Nov)
58.^Fontana E1, Morin N, Prévot D, Carpéné CEffects of octopamine on lipolysis, glucose transport and amine oxidation in mammalian fat cellsComp Biochem Physiol C Toxicol Pharmacol.(2000 Jan)
59.^Weyer C1, Gautier JF, Danforth E JrDevelopment of beta 3-adrenoceptor agonists for the treatment of obesity and diabetes--an updateDiabetes Metab.(1999 Mar)
60.^Alhasso A1, Glazener CM, Pickard R, N'dow JAdrenergic drugs for urinary incontinence in adultsCochrane Database Syst Rev.(2005 Jul 20)
61.^Jørgensen L1, Lose G, Alexander NAcute effect of norfenefrine on the urethral pressure profile in females with genuine stress incontinenceUrol Int.(1991)
62.^Lose G1, Rix P, Diernaes E, Alexander NNorfenefrine in the treatment of female stress incontinence. A double-blind controlled trialUrol Int.(1988)
63.^Lose G, Lindholm PClinical and urodynamic effects of norfenefrine in women with stress incontinenceUrol Int.(1984)
64.^Diernaes E1, Rix P, Sørensen T, Alexander NNorfenefrine in the treatment of female urinary stress incontinence assessed by one-hour pad weighing testUrol Int.(1989)
65.^David JC1, Coulon JF, Cavoy A, Delacour JEffects of aging on p- and m-octopamine, catecholamines, and their metabolizing enzymes in the ratJ Neurochem.(1989 Jul)
66.^Haller CA1, Benowitz NL, Jacob P 3rdHemodynamic effects of ephedra-free weight-loss supplements in humansAm J Med.(2005 Sep)
Primary Use